Evidence map›Paper›PMID 39885863›Full record

ArticleMolecular and clinical oncology2025

Safety study on switching from intravenous to fixed‑dose subcutaneous formulation of pertuzumab and trastuzumab.

Tomoya Abe, Atsunobu Sagara, Takayuki Suzuki, Daichi Okada, Daisuke Takei, Kazumasa Matsuzaka, Honoka Kobayashi, Makoto Hiraide, Motohiko Sano, Toshiaki Nakayama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomoya AbeDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Atsunobu SagaraDivision of Applied Pharmaceutical Education and Research, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo 142-8501, Japan.
Takayuki SuzukiDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Daichi OkadaDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Daisuke TakeiDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Kazumasa MatsuzakaDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Honoka KobayashiDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Makoto HiraideDivision of Applied Pharmaceutical Education and Research, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo 142-8501, Japan.
Motohiko SanoDivision of Applied Pharmaceutical Education and Research, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo 142-8501, Japan.
Toshiaki NakayamaDepartment of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To the best of our knowledge, there have been no reports from clinical settings regarding safety information on a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PHESGO

Indexed as

fixed-dose combinationinfusion reactioninjection site reactionsubcutaneous injectionswitching

Identifiers

PMID39885863
PMCPMC11775889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.